TECHNE CORPORATION
HomeCompany NewsFinancial InformationAbout TechneMap - DirectionsProductsContact Us

Segment Results - 2 nd Quarter Fiscal Year 2009

TECHNE CORPORATION AND SUBSIDIARIES
(in thousands of $’s, except per share data)

  Fiscal 2009 Increase(Decrease) From Fiscal 2008
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 69,324 61,876 131,200 100% 11,337 (266) 11,071
Cost of sales 13,086 13,430   26,516  20%     982     679  1,661
Gross margin 56,238 48,446 104,684 80% 10,355 (945) 9,410
               
Gross margin percentage 81.1% 78.3% 79.8%        
               
SG&A expense 8,840 9,703 18,543 14% 750 (942) (192)
R&D expense 5,910 5,846 11,756 9% 729 284 1,013
Amortization expense 240 240 480 - (48) (42) (90)
Interest income (2,887) (2,205) (5,092) (3%) 111 1,047 1,158
Other non-operating ex., net   1,187       712    1,899    1%     618    139     757
  13,290 14,296  27,586  21%  2,160    486  2,646
Earnings before income taxes 42,948 34,150 77,098 59% 8,195 (1,431) 6,764
Income taxes 14,355 10,528  24,883  19%  2,674 (1,414)  1,260
  28,593 23,622  52,215  40%  5,521     (17)  5,504
               
Diluted earnings per share .74 .62 1.36        
Weighted average diluted shares outstanding 38,747 37,992 38,370        

Back to Top
HEMATOLOGY DIVISION
(in thousands of $’s)

  Fiscal 2009 Increase(Decrease) From Fiscal 2008
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 4,246 4,260 8,506 100% 589 288 877
Cost of sales 2,369 2,405 4,774   56% 108  129 237
Gross margin 1,877 1,855 3,732 44% 481 159 640
               
Gross margin percentage 44.2% 43.5% 43.9%        
               
SG&A expense 436 398 834 10% (31) (89) (120)
R&D expense 193 203 396 4% 14 9 23
Interest, net (102)   (91) (193) (2%)   18    34      52
    527   510 1,037 12%     1 (46) (45)
Pretax result   1,350 1,345 2,695 32% 480 205 685

Back to Top
BIOTECHNOLOGY DIVISION (1)
(in thousands of $’s)

  Fiscal 2009 Increase(Decrease) From Fiscal 2008
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 53,899 48,643 102,542 100% 8,571 2,067 10,638
Intersegment sales (7,762) (8,311) (16,073)   (1,315)  (878) (2,193)
  46,137 40,332 86,469   7,256 1,189 8,445
               
Cost of sales 10,247 11,090 21,337 21% 1,250 1,478 2,728
Intersegment sales (7,461) (8,339) (15,800)   (1,287)  (909) (2,196)
  2,786 2,751 5,537   (37) 569 532
               
Gross margin 43,351 37,581 80,932 79% 7,293 620 7,913
               
Gross margin percentage 81.0% 77.2% 79.2%        
               
SG&A expense 5,141 5,418 10,559 10% 517 (116) 401
R&D expense 5,717 5,643 11,360 11% 715 275 990
Amortization expense 240 240 480 -- (48) (42) (90)
Interest, net (1,084) (970) (2,054) (1%) 173 339 512
Exchange loss/(gain)       (2)         1       (1)      --     (36)   (11)   (47)
  10,012 10,332 20,344 20%   1,321    445 1,766
Pretax result 33,339 27,249 60,588 59% 5,972    175 6,147

(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

Back to Top
R&D SYSTEMS EUROPE
(in thousands of £'s) 

  Fiscal 2009 Increase(Decrease) From Fiscal 2008
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 10,175 11,197 21,372 100% 2,570 1,896 4,466
Cost of sales 4,260  5,361   9,621  45%    805 1,308 2,113
Gross margin 5,915 5,836 11,751 55% 1,765 588 2,353
               
Gross margin percentage 58.1% 52.1% 55.0%        
               
SG&A expense 1,224 1,364 2,588 12% 110 88 198
Interest income (790) (583) (1,373) (6%) (107) 190 83
Exchange loss/(gain)    260    (35)      225   1%   356     46   402
      694    746   1,440   7%   359   324   683
Pretax result  5,221 5,090 10,311 48% 1,406   264 1,670

Back to Top
R&D SYSTEMS EUROPE
(in thousands of $’s)

  Fiscal 2009 Increase(Decrease) From Fiscal 2008
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 18,941 17,284 36,225 100% 3,492 (1,743) 1,749
Cost of sales  7,931   8,274 16,205   45%    911      (19)    892
Gross margin 11,010 9,010 20,020 55% 2,581 (1,724) 857
               
Gross margin percentage 58.1% 52.1% 55.3%        
               
SG&A expense 2,283 2,094 4,377 12% 21 (505) (484)
Interest income (1,471) (906) (2,377) (6%) (84) 670 586
Exchange loss     476        5     481   1%    674     170   844
   1,288 1,193  2,481   7%    611     335   946
Pretax result 9,722 7,817 17,539 48% 1,970 (2,059)  (89)

Back to Top
CORPORATE AND OTHER (2)
(in thousands of $’s)

  Fiscal 2009 Increase(Decrease) From Fiscal 2008
  First Quarter Second Quarter YTD First Quarter Second Quarter YTD
Interest income 230 238 468 (4) (4) (8)
Rental income      99  131   230 32   20  52
  329 369 698 28 16 44
             
SG&A expense 980 1,793 2,773 243 (232) 11
Other-Building expenses 553 551 1,104 9 (49) (40)
Other-Equity Investment losses      259   286    545    3    49   52
    1,792 2,630 4,422    255 (232)  23
Pretax result (1,463) (2,261) (3,724) (227)   248  21

Back to Top

(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC and Nephromics, LLC.



Home - Company News - Financial Information - About TECHNE - Map/Directions - Products - Contact Us

TECHNE CORPORATION
614 McKinley Place N.E.    Minneapolis, MN 55413-2610
Phone: (612)379-8854   Fax: (612)379-6580
e-mail: techinfo@techne-corp.com


* Up to a 15 minute delay on Market Overview. Please consult your financial advisor for an up-to-minute quote.
Quote provided by Barchart.com.